Atara Biotherapeutics (ATRA) Stock: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$9.38
-0.51 (-5.16%)
âŧ
5d:
-1.57%
30d:
+1.68%
90d:
-10.33%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATRA is fairly priced but lacks strong directional signals. At -24.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATRA is fairly priced but lacks strong directional signals. At -24.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.52
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$18.95
50.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $9.38, which is considered fair relative to its 30-day fair value range of $8.61 to $9.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.1) compared to its historical average (14.1). Remarkably, the market is currently pricing in an annual earnings decline of 24.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a uptrend. Immediate support is located at $8.80, while resistance sits at $11.33. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: ATRA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+45.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a uptrend. Immediate support is located at $8.80, while resistance sits at $11.33. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: ATRA scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+45.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.61 -
$9.73
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
45.2%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 45.7% below Wall St target ($13.67)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.61 -
$9.73
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.80
Resistance Level
$11.33
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.07
Wall Street Target
$13.67
(+45.7%)
Revenue Growth (YoY)
-96.4%
Profit Margin
-269.4%
Valuation Discount vs History
-24.6% cheaper
PE vs Historical
6.1 vs 14.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.6%
(market-implied from PE analysis)
1-Year Target
$8.44
(-10%)
2-Year Target
$7.60
(-19%)
3-Year Target
$6.84
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6â14)
$15.88
(+69%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.1 to 14.1
Stabilization Target:
$21.78
(+132.2%)
PE Expansion Potential:
+132.2%
Share & Embed Analysis
Last updated: September 13, 2026 3:16 PM ET
Data refreshes hourly during market hours. Next update: 4:16 PM
Data refreshes hourly during market hours. Next update: 4:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
